Skip to main content

Advertisement

Table 3 Treatment responses in patients treated with artesunate/amodiaquine, artemether/lumefantrine and dihydroartemisinin/piperaquine in Tanzania: PCR corrected

From: Efficacy and safety of artemisinin-based combination therapy, and molecular markers for artemisinin and piperaquine resistance in Mainland Tanzania

Year Drug/site N Excluded/lost Re-infection Uknown LCF LPF ACPR Kaplan–Meier
n (%) n (%) n (%) % (95% CI) % (95% CI) % (95% CI) % (95% CI)
2011 ASAQ
 Ujiji 73 8 (11.0) 12 (16.4) 3 (4.1) 0 (0.0–7.1) 2 (0.1–10.6) 98 (89.4–99.9) 98.3 (88.8–99.8)
 Kibaha 29 4 (13.8) NA NA 0 (0.0–13.7) 0 (0.0–13.7) 100 (86.3–100) 100
AL
 Muheza 32 2 (6.3) 0 1 (3.1) 0 (0.0–11.9) 0 (0.0–11.9) 100 (88.1–100) 100
2012 AL
 Chamwino 26 3 (11.5) 0 0 0 (0.0–14.8) 4.3 (0.1–21.9) 95.7 (78.1–99.0) 95.7 (72.9–99.4)
 Kyela 44 8 (18.2) 3 (6.8) 2 (4.5) 6.5 (0.8–21.4) 3.2 (0.1–16.7) 90.3 (74.2–98.0) 91.5 (75.9–97.2)
 Nagaga 62 23 (37.1) NA NA 0 (0.0–9.0) 0 (0.0–9.0) 100 (91.0–100) 100
2015 AL
 Kyela 80 16 (20.0) 3 (3.8) 1 (1.3) 0 (0.0–6.0) 0 (0.0–6.0) 100 (94.0–100) 100
DHA-PQ
 Rufiji 82 10 (12.2) 0 1 (1.2) 0 (0.0–5.1) 0 (0.0–5.1) 100 (94.9–100) 100
  1. Unknown unknown based on PCR analysis, LCF late clinical failure, LPF late parasitological failure, ACPR adequate clinical and parasitological response, ASAQ artesunate/amodiaquine, AL artemether/lumefantrine, DHAPQ dihydroartemisinin/piperaquine